

## 研究成果の刊行に関する一覧表

### 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
泉 並木	肝胆膵疾患の診療の進歩と留意点	泉 並木	今さら聞けない肝胆膵疾患	医学書院	東京	2021	390-393
泉 並木	B型肝炎ウイルスのキャリアといわれました		きょうの健康	NHK出版	東京	2020	115
泉 並木	総チェック！肝臓の病気 肝機能大丈夫？		きょうの健康	NHK出版	東京	2020	90-97
新川寛二、 久保正二	右肝切除（1）授動先行を採用する立場から（開腹下）	新田浩幸	ディベートから学ぶ手技の選択と秘訣「肝臓篇」	メジカルビュー社	東京	2021	73-82
久保正二、 笠原群生	肝移植	日本移植学会	臓器移植後妊娠・出産ガイドライン 2021	星雲社	東京	2021	67-74
田中肖吾、 久保正二	高齢消化器患者のADLや栄養の評価を实践できる	白石憲男、 上田貴威	高齢者に対する消化器外科のminimal requirements	メジカルビュー社	東京	2022	22-34
真木治文、 赤松延久、 長谷川潔	【専門医のための消化器病学】肝臓に対する肝移植基準の拡大	木下芳一、 金子周一、 樫田博史、 村上和成、 安藤朗、 糸井隆夫	専門医のための消化器病学 第3版	医学書院	東京	2021	480-482

### 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamauchi T, Yamamoto H, Miyata H, Kobayashi J, Masai T, Motomura N.	Surgical Aortic Valve Replacement for Aortic Stenosis in Dialysis Patients- Analysis of Japan Cardiovascular Surgery Database.	Circ J	84(8)	1271-1276	2020

Nakatsuka T, <u>Tateishi R</u> , Nakagomi R, Minami T, <u>Koike K</u> .	Risk Stratification of Hepatocellular Carcinoma after Hepatitis C Virus Eradication in Patients with Compensated Advanced Chronic Liver Disease in Japan.	J Hepatol	Online ahead of print	Epub2022 /03/16 doi: 10.1016/j.jhep.2022.03.002	2022
Sato M, Kobayashi T, Soroida Y, Tanaka T, Nakatsuka T, Nakagawa H, Nakamura A, Kurihara M, Endo M, Hikita H, Sato M, Gotoh H, Iwai T, <u>Tateishi R</u> , <u>Koike K</u> , Yatomi Y.	Development of Novel Deep Multimodal Representation Learning-Based Model for the Differentiation of Liver Tumors on B-Mode Ultrasound Images.	J Gastroenterol Hepatol	37(4)	678-84 Epub2021/12/16 doi: 10.1111/jgh.15763	2022
Nakagomi R, <u>Tateishi R</u> , Mikami S, Wake T, Kinoshita MN, Nakatsuka T, Minami T, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Shiina S, <u>Koike K</u> .	Infectious Complications Related to Radiofrequency Ablation of Liver Tumors: The Role of Antibiotics.	PLoS One	16(11)	e0259641 Epub2021/11/20 doi: 10.1371/journal.pone.0259641	2021
Kurokawa R, Inui S, Tanishima T, Nakaya M, Kurokawa M, Ishida M, Gono W, Amemiya S, Nakai Y, Ishigaki K, <u>Tateishi R</u> , <u>Koike K</u> , Abe O.	Incidence and Computed Tomography Findings of Lenvatinib-Induced Pancreatobiliary Inflammation: A Single-Center, Retrospective Study.	Medicine (Baltimore)	100(35)	e27182 Epub:2021/09/04 doi: 10.1097/MD.00000000000027182	2021
Nakatsuka T, <u>Tateishi R</u> , <u>Koike K</u> .	Changing Clinical Management of Nafld in Asia.	Liver Int	Online ahead of print	Epub2021/08/31 doi: 10.1111/liv.15046	2021
Minami T, <u>Tateishi R</u> , Fujiwara N, Nakagomi R, Nakatsuka T, Sato M, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Izumiya M, Hanajiri K, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Ohki T, Arai M, Tanaka A, Yasuda K,	Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after Hcv Eradication with Antivirals.	Liver Cancer	10(4)	309-19 Epub:2021/08/21 doi: 10.1159/000513705	2021

Miura H, Ogata I, Kamoshida T, Inoue K, Koike Y, Akamatsu M, Mitsui H, Fujie H, Ogura K, Yoshida H, Wada T, Kurai K, Maekawa H, Obi S, Teratani T, Masaki N, Nagashima K, Ishikawa T, Kato N, Moriya K, Yotsuyanagi H, <u>Koike K.</u>					
Yamada T, Minami T, <u>Tateishi R, Koike K.</u>	Limited Efficacy of Atezolizumab and Bevacizumab for Hepatocellular Carcinoma Previously Treated with Tyrosine Kinase Inhibitor.	Liver Int	41(9)	2233-34 pub2021/07/22 doi: 10.1111/li.v.15010	2021
Hangai S, Kawamura T, Kimura Y, Chang CY, Hibino S, Yamamoto D, Nakai Y, <u>Tateishi R,</u> Oshima M, Oshima H, Kodama T, Moriya K, <u>Koike K,</u> Yanai H, Taniguchi T.	Orchestration of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Ubiquitous Cellular Protein Tctp Released by Tumor Cells.	Nat Immunol	22(8)	947-57 Epub:2021/07/10 doi: 10.1038/s41590-021-00967-5	2021
Nakatsuka T, Nakagawa H, Hayata Y, Wake T, Yamada T, Nishibatake Kinoshita M, Nakagomi R, Sato M, Minami T, Uchino K, Enooku K, Kudo Y, Tanaka Y, Kishikawa T, Otsuka M, <u>Tateishi R, Koike K.</u>	Post-Treatment Cell-Free DNA as a Predictive Biomarker in Molecular-Targeted Therapy of Hepatocellular Carcinoma.	J Gastroenterol	56(5)	456-69 Epub2021/03/14 doi: 10.1007/s00535-021-01773-4	2021
Uchino K, <u>Tateishi R,</u> Wake T, Kinoshita MN, Nakagomi R, Nakatsuka T, Minami T, Sato M, Enooku K, Nakagawa H, Shiina S, <u>Koike K.</u>	Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy: A Case-Control Analysis of over 10,000 Treatments.	J Vasc Interv Radiol	32(6)	869-77 Epub2021/03/11 doi: 10.1016/j.jvir.2021.02.021	2021
建石 良介, 小池 和彦.	クラウドを基盤としたガイドラ	肝臓	62(8)	512-15	2021

	イン支援システムの開発と実装				
Hayakawa Y, Tsuchiya K, Kurosaki M, Yasui Y, Kaneko S, Tanaka Y, Ishido S, Inada K, Kirino S, Yamashita N, Nobusawa T, Matsumoto H, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, <u>Izumi N.</u>	Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.	Invest New Drugs	40	392-402	2022
Tsuchiya K, Kurosaki M, Sakamoto A, Marusawa H, Kojima Y, Hasebe C, Arai H, Joko K, Kondo M, Tsuji K, Sohda T, Kimura H, Ogawa C, Uchida Y, Wada S, Kobashi H, Furuta K, Shigeno M, Kusakabe A, Akahane T, Narita R, Yoshida H, Mitsuda A, Ide Y, Matsushita T, <u>Izumi N.</u>	The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.	Cancers	13	2608	2021
Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, <u>Izumi N.</u>	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus.	Hepatol Commun.	Oct 22	Doi:10.1002/hep4.1833.	2021
Kirino S, Tamaki N, Kurosaki M, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa	Dynamic evaluation of hepatocellular carcinoma models in patients with chronic hepatitis receiving nucleotide/nucleoside	J Viral Hepatit	28	787-794	2021

L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, <u>Izumi N.</u>	analogue treatment.				
Inada K, Kaneko S, Kurosaki M, Yamashita K, Kirino S, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, <u>Izumi N.</u>	Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivatiobn and de novo hepatitis.	JGH open	5	1085-1091	2021
Tamaki N, Kurosaki M, Nakanishi H, Itakura J, Inada K, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Takahashi Y, <u>Izumi N.</u>	Comparison of medication adherence and stratification between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.	J Med Virol	92	1355-1358	2020
Sakura Kirino , Nobuharu Tamaki, Shun Kaneko, Masayuki Kurosaki , Kento Inada, Koji Yamashita, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Keiya Watakabe, Mao Okada, Wan Wang, Takao Shimizu, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Yutaka Yasui, Hiroyuki	Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.	J Gastroentero l Hepatol.	35	1595-1601	2020

Nakanishi, Kaoru Tsuchiya, Jun Itakura, Yuka Takahashi, <u>Namiki</u> <u>Izumi.</u>					
Sakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Koji Yamashita, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mao Okada, Wan Wang, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, <u>Namiki</u> <u>Izumi.</u>	Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.	PLoS One	15	E0231828	2020
Shun Kaneko, Masayuki Kurosaki, Kouji Joko, Hiroyuki Marusawa, Masahiko Kondo, Yuji Kojima, Yasushi Uchida, Hiroyuki Kimura, Keiji Tsuji, Hitoshi Yagisawa, Atsunori Kusakabe, Haruhiko Kobashi, Takehiro Akahane, Nobuharu Tamaki, Sakura Kirino, Takehiko Abe, Hideo Yoshida, Tomomichi Matsushita, Chitomi Hasebe, <u>Namiki</u> <u>Izumi.</u>	Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.	Sci Rep	10	13021	2020
Shun Kaneko, Kaoru Tsuchiya, Yutaka Yasui, Kento Inada, Sakura Kirino, Koji Yamashita, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mayu	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis.	Hepatol Res	50	1375-1385	2020

Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Takaya Takeguchi, Yuko Takeguchi, Takuya Nagano, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yoshiro Himeno, Akihiko Hoshi, Masayuki Kurosaki, Namiki Izumi,					
<u>Kanto T.</u>	Messages from Japan policy for viral hepatitis.	Global Health & Medicine,	3(5)	249-252	2021
Takeuchi Y, Ohara M and <u>Kanto T*</u> .	Nationwide awareness-raising program for viral hepatitis in Japan: the “Shitte kan-en” project.	Global Health & Medicine,	3(5)	301-307	2021
Setoyama H, Tanaka Y and <u>Kanto T*</u> .	Seamless support from screening to anti-HCV treatment and HCC/decompensated cirrhosis: Subsidy programs for HCV elimination	Global Health & Medicine,	3(5)	335-342	2021
Korenaga M and <u>Kanto T*</u> .	Testing, diagnosis of viral hepatitis, and the follow-up policy in Japan.	Global Health & Medicine,	3(5)	308-313	2021
Itakura, J; Kurosaki, M; Setoyama, H; Simakami, T; Oza, N; Korenaga, M; Tanaka, M; Torimura, T; Sakamoto, N; Enomoto, N; Ueno, Y; Kawada, N; Kaneko, S; Nishiguchi, S; Chayama, K; Tanaka, J; Izumi, N; <u>Kanto, T*</u> .	Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.	J. Gastroenterol .	56(5)	470-478	2021
<u>Kudo M</u> , Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A,	A randomized, double-blind, placebo-controlled, phase III study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.	Cancer Sci	111	3759-3769	2021

Sato T, Ikawa Y, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J					
Hughes DM, Berhane S, de Groot CAE, Toyoda H, Tada T, Kumada T, Satomura S, Nishida N, <u>Kudo M</u> , Kimura T, Osaki Y, Kolamunage-Dona R, Salvador RA, Bird T, Garcia-Finana M, Johnson P	Serum levels of alpha fetoprotein increased more than 10 years before detection of hepatocellular carcinoma.	Clin Gastroenterol Hepatol	19	162-170	2021
<u>Kudo M</u> , Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX	Effect of ramucirumab or best supportive care on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.	JHEP Reports	3	100215  <a href="https://doi.org/10.1016/j.jhepr.2020.100215">https://doi.org/10.1016/j.jhepr.2020.100215</a>	2021
Ikeda S, <u>Kudo M</u> , Izumi N, Kobayashi M, Azuma M, Meier G, Pan J, Ishii M, Kaneko S	Cost-effectiveness of lenvatinib in the treatment of patients with unresectable hepatocellular carcinomas in Japan: An analysis using data from Japanese patients in the REFLECT trial.	Value Health Reg Issues	24	82-89	2021
Chen M, Cao J, Hu J, Topatana W, Li S, Juengpanich S, Lin J, Tong C, Shen J, Zhang B, Wu J, Pocha C, <u>Kudo M</u> , Amedei A, Trevisani F, Sung PS, Zaydfudim VM, Kanda T, Cai X	Clinical-radiomic analysis for pretreatment prediction of objective response to first transarterial chemoembolization in hepatocellular carcinoma.	Liver Cancer	10	38-51	2021
<u>Kudo M</u>	Impact of multi-drug sequential therapy on survival in patients with unresectable hepatocellular carcinoma.	Liver Cancer	10	1-9	2021
<u>Kudo M</u> , Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda	Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: A Phase II multicenter study.	J Gastroenterol	56	181-190	2021



S, Kimura A					
Reig M, Galle PR, <u>Kudo M</u> , Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.	Liver Int	41	598-607	2021
<u>Kudo M</u> , Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S	Report of the 21st nationwide follow-up survey of primary liver cancer in Japan (2010–2011)	Hepatol Res	51	355-405	2021
Aoki T, Kubota K, Kubo S, Eguchi S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, <u>Kudo M</u>	Analysis of patient outcome after non-curative resection for hepatocellular carcinoma using nationwide survey data in Japan.	World J Surg	45	607-614	2021
Minami Y, Minami T, Ueshima K, Yagyū Y, Tsurusaki M, Okada T, Hori M, <u>Kudo M</u> , Murakami T	Three-dimensional radiological assessment of ablative margins in hepatocellular carcinoma: Pilot study of overlay fused CT/MRI imaging with automatic registration.	Cancers	13	1460	2021
Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle P, Lencioni R, Greten TF, <u>Kudo M</u> , Mandrekar SJ, Zhu AX, Finn RS, Roberts LR, for Panel of AASLD experts on Trial Design in HCC	Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference.	Hepatology	73	158-191	2021
Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P,	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.	Brit J Cancer	124	1388-1397	2021

<u>Kudo M</u>					
Minami Y, <u>Kudo M</u>	Image guidance in ablation for hepatocellular carcinoma: Contrast-enhanced ultrasound and fusion imaging.	Front Oncol	11	593636	2021
Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, <u>Kudo M</u>	Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.	Cancer	127	865-874	2021
Zhang T, Merle P, Wang H, Zhao H, <u>Kudo M</u>	Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?	Hepatobiliary Surg Nutr	10	180-192	2021
Hagiwara S, Watanabe T, <u>Kudo M</u> , Minaga K, Komeda Y, Kamata K, Kimura M, Hayashi H, Nakagawa K, Ueshima K, Minami Y, Aoki T, Takita M, Morita M, Chishina H, Ida H, Park AM, Nishida N	Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease.	Sci Rep	11	9242	2021
<u>Kudo M</u>	Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: Present and future perspective.	Hepatobil Surg Nutr	10	241-245	2021
Hajiev S, Allara E, Motedayen-Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, <u>Kudo M</u> , Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R	Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.	Brit J Cancer	124	407-413	2021
Hiraoka A, Kumada T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M,	What can be done to solve the unmet clinical need of hepatocellular carcinoma patients following lenvatinib	Liver Cancer	10	115-125	2021

Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, <u>Kudo M</u> , On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)	failure?				
Hajiev S, Allara E, Motedayen-Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, <u>Kudo M</u> , Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R: Correction	Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.	Brit J Cancer	124	1611	2021
<u>Kudo M</u>	Sequential therapy for hepatocellular carcinoma after failure of atezolizumab plus bevacizumab combination therapy.	Liver Cancer	10	85-93	2021
Okusaka T, Ikeda K, <u>Kudo M</u> , Finn RS, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Mody K, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.	J Gastroenterol	56	570-580	2021
<u>Kudo M</u> , Ikeda M, Galle P, Yamashita T, Finn RS, Liang K, Wang C, Sakaguchi S,	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes by	Hepatol Res	51	715-721	2021

Abada P, Widau RC, Zhu AX	treatment-emergent ascites.				
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, <u>Kudo M</u> , On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.	Cancer Rep		e1464	2021
Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, <u>Kudo M</u> , Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomized, phase 3 trial.	Lancet Oncol	22	991-1001	2021
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydłowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Youssuf S, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Heide D, Moncsek A, Stirm K, Kosla J, Prokosch S, Rothermel U, Dudek M, Kotsiliti E, O'Connor T, Leone V, Inverso D, Jansen J, Singh I, Yabal M,	NASH limits anti-tumor surveillance in immunotherapy-treated HCC.	Nature	592	450-456	2021

<p>Castet F, Montironi C, Haber PK, Torrecilla S, Eichwald V, Jugold M, Ollinger R, Matter M, Terracciano L, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratzu V, Rimassa L, Daly AK, Scheiner B, Romej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann A, Bueter M, Roessler F, Schmid J, Müllhaupt B, Kaeser R, Boettler T, Thimme R, Siebenhüner A, De Dosso S, Augustin HG, Schietinger A, Groth C, Umansky V, Billeter A, Müller-Stich B, Mallm JP, Mei H, Schulz A, Luedde T, Ringelhan M, Malek N, Spahn S, Bitzer M, Schirmacher P, Longerich T, Ranbari N, Dufour JF, Marron TU, Kaseb A, <u>Kudo M</u>, Huang YH, Teijeiro A, Djouder N, Weber A, Marche P, Pinato DJ, Decaens T, Jilkova ZM, Rad R, Mertens JC, Unger K, Meissner F, Roth S, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M</p>					
<p>Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY</p>	<p>Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of Asian Patients in the Phase 3 KEYNOTE-240 trial.</p>	<p>Liver Cancer</p>	<p>10</p>	<p>275-284</p>	<p>2021</p>

<u>Kudo M</u> , Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J	Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: results from the phase 1b VEGF Liver 100 trial.	Liver Cancer	10	249-259	2021
<u>Kudo M</u> , Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T, on behalf of the HCC Expert Panel of the Japan Society of Hepatology	Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2020 update.	Liver Cancer	10	181-223	2021
<u>Kudo M</u>	Surveillance, diagnosis, treatment outcomes of hepatocellular carcinoma in Japan: 2021 update.	Liver Cancer	10	167-180	2021
Vogel A, Qin S, <u>Kudo M</u> , Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Otsuka T, Tamai T, Bennett L, Meier G, Breder V	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.	Lancet Gastroenterol Hepatol	6	649-658	2021
Hagiwara S, Nishida N, Ueshima K, Yoshida A, Minami Y, <u>Kudo M</u>	Comparison of efficacy and safety of the treatment of entecavir and switching entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long term effects of the prospective study.	Hepatol Res	51	767-774	2021
<u>Kudo M</u>	Impaired response to immunotherapy in non-alcoholic steatohepatitis-related hepatocellular carcinoma?	Liver Cancer	10	289-295	2021
Morita M, Nishida N, Sakai K, Aoki T,	Immunological microenvironment predicts the	Liver Cancer	10	380-393	2021

Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Nishio K, Kobayashi Y, Kakimi K, <u>Kudo M</u>	survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody.				
<u>Kudo M</u>	Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma.	Hepatobil Surg Nutr	10	522-525	2021
Kaibori M, Yoshii K, Kashiwabara K, Kokudo T, Hasegawa K, Izumi N, Murakami T, <u>Kudo M</u> , Shiina S, Sakamoto M, Nakashima O, Matsuyama Y, Eguchi S, Yamashita T, Takayama T, Kokudo N, Kubo S	Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: report of a Japanese nationwide survey.	Hepatol Res	51	890-901	2021
Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohma H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Ogawa C, Tamai T, Kakizaki S, Nagashima T, Ueno T, Tojima H, Takizawa D, Naganuma A, Okubo T, <u>Kudo M</u>	Therapeutic efficacy of lenvatinib as third line treatment following regorafenib for unresectable hepatocellular carcinoma progression.	Hepatol Res	51	880-889	2021
Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K,	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: Multi-center retrospective study.	Sci Rep	11:16663, 2021. doi.org/10.1038/s41598-021-96089-x		2021

Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Aoki T, anaka T, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, <u>Kudo M</u> , the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group: Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology					
<u>Kudo M</u> , Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.	J Hepatol	75	600-609	2021
Minami Y, Morita M, Chishina H, Aoki T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, <u>Kudo M</u>	Can the entire ablative hyperechoic zone be regarded as a necrotic lesion after radiofrequency ablation of the liver?	Ultrasound Med Biol	47	2930-2935	2021
Finn RS, <u>Kudo M</u> , Cheng AL, Wyrwicz L, Ngan RKC, Blanc JF, Baron AD, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus CE, Ikezawa H, Funahashi Y, Evans TRJ	Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the Phase 3 REFLECT study.	Clin Cancer Res	27	4848-4858	2021



Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, David WM Tai, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Parmd MM, Negro A, <u>Kudo M</u> , Abou-Alfa GK	Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a Phase I/II study.	J Clin Oncol	39	2991-3001	2021
Vogel A, Merle P, Verslype C, Finn RS, Zhu AX, Cheng AL, Chan SL, Yau T, Ryoo BY, Knox J, Daniele B, Qin S, Wei Z, Miteva Y, Malhotra U, Siegel AB, <u>Kudo M</u>	ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.	Ther Adv Med Oncol	13	17588359211039928, 2021. doi: 10.1177/17588359211039928.	2021
Gandhi M, Ling WH, Chen CH, Lee JH, <u>Kudo M</u> , Chanwat R, Strasser SS, Xu Z, Lai SH, Chow PK	Impact of COVID-19 on hepatocellular carcinoma management: A multicountry and region study.	J Hepatocell Carcino	8	1159-1167	2021
<u>Kudo M</u>	Adjuvant immunotherapy after curative treatment for hepatocellular carcinoma.	Liver Cancer	10	399-403	2021
Vogel A, Frenette C, Sung M, Daniele B, Baron A, Chan SL, Blanc JF, Tamai T, Ren M, Lim HJ, Palmer DH, Takami Y, <u>Kudo M</u>	Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma.	Liver Cancer	10	510-521	2021
Hagiwara S, Nishida N, <u>Kudo M</u>	Improved tumor response to lenvatinib re-treatment after failure of immune checkpoint inhibitors in a patient with advanced hepatocellular carcinoma.	Liver Cancer	10	535-538	2021
<u>Kudo M</u> , Finn R, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet J, Daniele B, Lim HY, Mellwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX	Ramucirumab for patients with intermediate-stage hepatocellular carcinoma and elevated alpha-fetoprotein: pooled results from two phase 3 studies (REACH and REACH-2).	Liver Cancer	10	451-460	2021

Yamashita Y, Shimokawa T, Ashida R, Dietrich CF, D'Onofrio M, Hirooka Y, <u>Kudo M</u> , Mori H, Sofuni A, Kitano M	Value of low-mechanical-index contrast-enhanced transabdominal ultrasound for diagnosis of pancreatic cancer: A meta-analysis.	Ultraound Med Biol	47	3315-3322	2021
Galle PR, <u>Kudo M</u> , Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Touchefeu Y, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease etiology.	Liver Int	41	2759-2767	2021
<u>Kudo M</u>	Changing the treatment paradigm for hepatocellular carcinoma using atezolizumab plus bevacizumab combination therapy.	Cancers	13	5475	2021
Hagiwara S, Nishida N, Ueshima K, Minami Y, Komeda Y, Aoki T, Takita M, Morita M, Chishina H, Yoshida A, Ida H, <u>Kudo M</u>	Accumulation of genetic and epigenetic alterations in the background liver and emergence of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.	Cells	10	3257	2021
Sakai K, Sakurai T, De Velasco MA, Nagai T, Chikugo T, Ueshima K, Kura Y, Takahama T, Hayashi H, Nakagawa K, <u>Kudo M</u> , Nishio K	Intestinal microbiota and gene expression reveal similarity and dissimilarity between Immune-mediated colitis and ulcerative colitis.	Front Oncol	11	763468	2021
<u>Kudo M</u>	A novel treatment strategy for patients with Intermediate-stage HCC who are not suitable for TACE: Upfront systemic therapy followed by curative conversion.	Liver Cancer	10	539-544	2021
Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Scheiner B, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B,	Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma.	Liver Cancer	10	583-592	2021

Paul S, Nimkar N, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Personeni N, Nishida N, <u>Kudo M</u> , Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellijni A, Pinato DJ					
Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, <u>Kudo M</u>	Higher enhancement intrahepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a poor responsive marker of anti-PD-1 / PD-L1 monotherapy for unresectable hepatocellular carcinoma.	Liver Cancer	10	615-628	2021
Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Michitaka K, Hiasa Y, <u>Kudo M</u> , on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)	Clinical importance of muscle volume in lenvatinib for hepatocellular carcinoma: analysis adjusted with inverse probability weighting.	J Gastroenterol Hepatol	36	1812-1819	2021
Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, <u>Kudo M</u> , Lee JM, Murakami T, Seidensticker M,	Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoteric acid-enhanced imaging.	Eur Radiol	31	5615-5628	2021

SirlinCB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B					
Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giulante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, <u>Kudo M</u> , Kokudo N	Effect of diameter and number of hepatocellular carcinomas on survival after resection, trans-arterial chemoembolization, and ablation.	Am J Gastroenterol	116	1698-1708	2021
Muhammed A, Fulgenzi CAM, Pinter M, Balcar L, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Navaid M, Naqash AR, Gampa A, Vincenzi B, Silletta M, Pillai A, Wang Y, Muzaffar M, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Tommaso LD, <u>Kudo M</u> , Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Pinato DJ	The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma.	Cancers	14	186, 2021 doi: 10.3390/cancers14010186.	2021
Matsui T, <u>Kubo S</u> , et al.	Identification of microRBA-96-5p as a postoperative, prognostic microRNA predictor in non-viral hepatocellular carcinoma	Hepatology Research	52 (1)	93-104	2022
Kawaguchi Y, <u>Kubo S</u> , et al.	Effect of diameter and number of hepatocellular carcinomas on survival after resection, trans-arterial chemoembolization, and	American Journal of Gastroenterology	116 (8)	1698-1708	2021

	ablation				
Iida H, <u>Kubo S</u> , et al.	Risk factors for incisional hernia according to different wound sites after open hepatectomy using combinations of vertical and horizontal incisions: A multicenter cohort study	Annals of Gastroenterological Surgery	5 (5)	701-710	2021
Kaibori M, <u>Kubo S</u> , et al.	Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: report of a Japanese nationwide survey	Hepatology Research	51 (8)	890-901	2021
Tanaka S, <u>Kubo S</u> , et al.	Postoperative direct-acting antiviral treatment after liver resection in patients with hepatitis C virus-related hepatocellular carcinoma	Hepatology Research	51 (11)	1102-1114	2021
Kinoshita M, <u>Kubo S</u> , et al.	Impact of advancing age on the status and risk of postoperative infection after liver resection	World Journal of Surgery	45 (11)	3386-3394	2021
Shirai D, <u>Kubo S</u> , et al.	Impact of alcohol abstinence on survival after hepatic resection for hepatocellular carcinoma in patients with alcohol-related liver disease	Annals of Medicine and Surgery (London)	68	102644	2021
Shinkawa H, <u>Kubo S</u> , et al.	The prognostic impact of tumor differentiation on recurrence and survival after resection of hepatocellular carcinoma Is dependent on tumor size	Live Cancer	10 (5)	461-472	2021
Kinoshita M, <u>Kubo S</u> , et al.	Indications of laparoscopic repeat liver resection for recurrent hepatocellular carcinoma	Annals of Gastroenterological Surgery	6 (1)	119-126	2021
Ishihara A, <u>Kubo S</u> , et al.	Superiority of laparoscopic liver resection to open liver resection in obese individuals with hepatocellular carcinoma	Annals of Gastroenterological Surgery	6 (1)	135-148	2021
Shinkawa H, <u>Kubo S</u> , et al.	Impact of laparoscopic parenchyma-sparing resection of lesions in the right posterosuperior liver segments on surgical outcomes: a multicenter study based on	Surgery			In press

	propensity score analysis				
<u>Kubo S</u> , et al.	Liver Cancer Study Group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma	Liver Cancer			In press
Takeji Y, Yamamoto H, Ueno H, Eguchi S, Endo I, Sasaki A, Takiguchi S, Takeuchi H, Hashimoto M, Horiguchi A, Masaki T, Marubashi S, Yoshida K, <u>Miyata H</u> , Konno H, Gotoh M, Kitagawa Y, Mori M, Seto Y.	Development of gastroenterological surgery over the last decade in Japan: analysis of the National Clinical Database.	Surg Today.	51(2)	187-193	2021
Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Shimizu H, Okada M, Toh Y, Doki Y, Endo S, Fukuda H, Hirata Y, Iwata H, Kobayashi J, Kumamaru H, <u>Miyata H</u> , Motomura N, Natsugoe S, Ozawa S, Saiki Y, Saito A, Saji H, Sato Y, Taketani T, Tanemoto K, Tangoku A, Tatsuishi W, Tsukihara H, Watanabe M, Yamamoto H, Minatoya K, Yokoi K, Okita Y, Tsuchida M, Sawa Y.	Thoracic and cardiovascular surgeries in Japan during 2018 : Annual report by the Japanese Association for Thoracic Surgery.	Gen Thorac Cardiovasc Surg.	69(1)	179-212.	2021
Watanabe M, Tachimori Y, Oyama T, Toh Y, Matsubara H, Ueno M, Kono K, Uno T, Ishihara R, Muro K, Numasaki H, Tanaka K, Ozawa S, Murakami K, Usune S, Takahashi A, <u>Miyata H</u> ; Registration Committee for Esophageal Cancer of the Japan Esophageal	Comprehensive registry of esophageal cancer in Japan, 2013.	Esophagus.	18(1)	1-24.	2021

Society.					
Tatsuishi W, Kumamaru H, Nakano K, <u>Miyata H</u> , Motomura N.	Evaluation of postoperative outcomes of valve reoperation: a retrospective study.	Eur J Cardiothorac Surg.	59(4)	869-877.	2021
Hirahara N, <u>Miyata H</u> , Kato N, Hirata Y, Murakami A, Motomura N.	Development of Bayesian Mortality Categories for Congenital Cardiac Surgery in Japan.	Ann Thorac Surg.	112(3)	839-845	2021
Tamura Y, Kumamaru H, Abe K, Satoh T, <u>Miyata H</u> , Ogawa A, Tanabe N, Hatano M, Yao A, Tsujino I, Fukuda K, Kimura H, Kuwana M, Matsubara H, Tatsumi K; Japan Pulmonary Hypertension Registry (JAPHR) Network.	Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR).	BMC Pulm Med.	21(1)	28	2021
Fujishiro J, Fujiogi M, Hirahara N, Terui K, Okamoto T, Watanabe E, Ishimaru T, <u>Miyata H</u> .	Abdominal Drainage at Appendectomy for Complicated Appendicitis in Children: A Propensity-matched Comparative Study.	Ann Surg.	274(6)	e599-e604	2021
Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, <u>Miyata H</u> , Kubo S.	Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011).	Hepatol Res.	51(4)	355-405	2021
Saito A, Kumamaru H, <u>Miyata H</u> , Motomura N.	Device Use for Proximal Anastomosis on Ascending Aorta in Off-Pump Coronary Artery Bypass Grafting.	Ann Thorac Surg.	111(6)	1909-1915	2021
Yamashita YI, Yamamoto H, <u>Miyata H</u> , Kakeji Y, Kitagawa Y, Yamaue H, Yamamoto M, Baba H.	Risk factors for bile leakage: Latest analysis of 10 102 hepatectomies for hepatocellular carcinoma from the Japanese national clinical database.	J Hepatobiliary Pancreat Sci.	28(7)	556-562	2021
Sawaki M, Yamada A, Kumamaru H, <u>Miyata H</u> , Nakayama	Clinicopathological characteristics, practical treatments, prognosis, and	Breast Cancer.	28(1)	1-8	2021

K, Shimizu C, Miyashita M, Honma N, Taira N, Saji S.	clinical issues of older breast cancer patients in Japan.				
Watanabe M, Toh Y, Ishihara R, Kono K, Matsubara H, Murakami K, Muro K, Numasaki H, Oyama T, Ozawa S, Saeki H, Tanaka K, Tsushima T, Ueno M, Uno T, Yoshio T, Usune S, Takahashi A, <u>Miyata H</u> ; Registration Committee for Esophageal Cancer of the Japan Esophageal Society.	Comprehensive registry of esophageal cancer in Japan, 2014.	Esophagus.	Online ahead of print.		2021
Kohsaka S, Kumamaru H, Nishimura S, Shoji S, Nakatani E, Ichihara N, Yamamoto H, Miyachi Y, <u>Miyata H</u> .	Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose-lowering agents: A population-based community study from the Shizuoka Kokuho database.	J Diabetes Investig.	12(8)	1452-1461	2021
Saito A, Kumamaru H, Motomura N, <u>Miyata H</u> , Takamoto S.	Status of cardiovascular surgery in Japan between 2017 and 2018: A report based on the Cardiovascular Surgery Database. 2. Isolated coronary artery bypass surgery.	Asian Cardiovasc Thorac Ann.	29(4)	294-299	2021
Iwatsuki M, Yamamoto H, <u>Miyata H</u> , Kakeji Y, Yoshida K, Konno H, Seto Y, Baba H.	Association of surgeon and hospital volume with postoperative mortality after total gastrectomy for gastric cancer: data from 71,307 Japanese patients collected from a nationwide web-based data entry system.	Gastric Cancer.	24(2)	526-534	2021
Abe T, Kumamaru H, Nakano K, Motomura N, <u>Miyata H</u> , Takamoto S.	Status of cardiovascular surgery in Japan between 2017 and 2018: A report based on the Japan Cardiovascular Surgery Database. 3. Valvular heart surgery.	Asian Cardiovasc Thorac Ann.	29(4)	300-309	2021
Shimizu H, Hirahara N, Motomura N, <u>Miyata H</u> , Takamoto S.	Status of cardiovascular surgery in Japan between 2017 and 2018: A report based on the Japan Cardiovascular Surgery Database. 4. Thoracic	Asian Cardiovasc Thorac Ann.	29(4)	278-288	2021



	aortic surgery.				
Ban D, Tanabe M, Kumamaru H, Nitta H, Otsuka Y, <u>Miyata H</u> , Kakeji Y, Kitagawa Y, Kaneko H, Wakabayashi G, Yamaue H, Yamamoto M.	Safe Dissemination of Laparoscopic Liver Resection in 27,146 Cases Between 2011 and 2017 From the National Clinical Database of Japan.	Ann Surg.	274(6)	1043-1050	2021
Sawano M, Spertus JA, Masoudi FA, Rumsfeld JS, Numasawa Y, Inohara T, Kennedy K, Ueda I, <u>Miyata H</u> , Fukuda K, Kohsaka S.	Bleeding avoidance strategies and percutaneous coronary intervention outcomes: A 10-year observation from a Japanese Multicenter Registry.	Am Heart J	235	113-124	2021
Fujishiro J, Watanabe E, Hirahara N, Terui K, Tomita H, Ishimaru T, <u>Miyata H</u> .	Laparoscopic Versus Open Appendectomy for Acute Appendicitis in Children: a Nationwide Retrospective Study on Postoperative Outcomes.	J Gastrointest Surg	25(4)	1036-1044	2021
Hirata Y, Hirahara N, Murakami A, Motomura N, <u>Miyata H</u> , Takamoto S.	Status of cardiovascular surgery in Japan: A report based on the Japan Cardiovascular Surgery Database 2017-2018. 1. Congenital heart surgery.	Asian Cardiovasc Thorac Ann.	29(4)	289-293	2021
Ueki C, Yamamoto H, Motomura N, <u>Miyata H</u> , Sakata R, Tsuneyoshi H.	Effect of Hospital and Surgeon Procedure Volumes on the Incidence of Intraoperative Conversion During Off-Pump Coronary Artery Bypass Grafting.	Semin Thorac Cardiovasc Surg.	33(1)	49-58	2021
Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, <u>Tateishi R</u> , Ogawa M, Mori H, Kitano M, Toyoda H, Ogawa C, Kudo M, investigators JAI.	Artificial Intelligence (Ai) Models for the Ultrasonographic Diagnosis of Liver Tumors and Comparison of Diagnostic Accuracies between Ai and Human Experts.	J Gastroenterol	57(4)	309-21 Epub:2022/02/28 doi: 10.1007/s00535-022-01849-9	2022
Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, <u>Tateishi R</u> , Nouse K, Hasegawa K,	Response Evaluation Criteria in Cancer of the Liver Version 6 (Response Evaluation Criteria in Cancer of the Liver	Hepatol Res	52(4)	329-36 Epub:2022/01/26 doi: 10.1111/he	2022

Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N.	2021 Revised Version)			pr.13746	
Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsushashi H, Itoh Y, <u>Tateishi R</u> , Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.	Liver-Related Events after Direct-Acting Antiviral Therapy in Patients with Hepatitis C Virus-Associated Cirrhosis.	J Gastroenterol	57(2)	120-32 Epub:2022/01/22 doi: 10.1007/s00535-021-01845-5	2022
Yoshida M, <u>Tateishi R</u> , Hiroi S, Fujiwara M, Kitanishi Y, Iwasaki K, Takeshima T, Igarashi A.	Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data.	Adv Ther	39(2)	992-1003 Epub:2021/12/21 doi: 10.1007/s12325-021-02008-x	2022
Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, <u>Tateishi R</u> , Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S.	Report of the 22nd Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2012-2013).	Hepatol Res	52(1)	5-66 Epub2021/05/30 doi: 10.1111/hopr.13675	2022
Miki N, Inoue S, Shibahara H, Kurazono K, Perard R, <u>Tateishi R</u> .	A Cost-Effectiveness Analysis of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease in Japan.	JGH Open	5(8)	879-87 Epub:2021/08/14 doi: 10.1002/jgh3.12597	2021
Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H,	A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis.	Med (N Y)	2(7)	836-50 e10 Epub:2021/07/29 doi: 10.1016/j.medj.2021.03.017	2021

<u>Tateishi R</u> , Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y.					
Kudo M, Kawamura Y, Hasegawa K, <u>Tateishi R</u> , Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T.	Management of Hepatocellular Carcinoma in Japan: Jsh Consensus Statements and Recommendations 2021 Update.	Liver Cancer	10(3)	181-223 Epub:2021/07/10 doi: 10.1159/00514174	2021
Abe-Doi M, Murayama R, Komiyama C, <u>Tateishi R</u> , Sanada H.	Effectiveness of Ultrasonography for Peripheral Catheter Insertion and Catheter Failure Prevention in Visible and Palpable Veins.	J Vasc Access	Online ahead of print.	Epub:2021/06/03 doi: 10.1177/11297298211022078	2021
Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, <u>Tateishi R</u> , Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giuliani F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N.	Effect of Diameter and Number of Hepatocellular Carcinomas on Survival after Resection, Transarterial Chemoembolization, and Ablation.	Am J Gastroenterol	116(8)	1698-708 Epub2021/04/27 doi: 10.14309/ajg.000000000001256	2021
Ichida A, Akamatsu N, Nagata R, Mihara Y, Kawaguchi Y, Bae SK, Ishizawa T, Kaneko J, Arita J, <u>Hasegawa K</u> .	Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.	Anticancer Res.	42(2)	1161-1167	2022

Kokudo T, <u>Hasegawa K</u> .	Evaluating the liver function of patients with hepatocellular carcinoma.	Hepatol Res.	51(11)	1095-1096	2021
Arita J, Yamamoto H, Kokudo T, <u>Hasegawa K</u> , Miyata H, Toh Y, Gotoh M, Kokudo N, Kakeji Y, Yasuyuki S.	Impact of board certification system and adherence to the clinical practice guidelines for liver cancer on post-hepatectomy risk-adjusted mortality rate in Japan: A questionnaire survey of departments registered with the National Clinical Database.	J Hepatobiliary Pancreat Sci.	28(10)	801-811	2021
Kaibori M, Yoshii K, Kashiwabara K, Kokudo T, <u>Hasegawa K</u> , Izumi N, Murakami T, Kudo M, Shiina S, Sakamoto M, Nakashima O, Matsuyama Y, Eguchi S, Md, Yamashita T, Md, Takayama T, Kokudo N, Kubo S; Liver Cancer Study Group of Japan.	Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: report of a Japanese nationwide survey.	Hepatol Res.	51(8)	890-901	2021
Kawaguchi Y, <u>Hasegawa K</u> , Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giuliani F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N. Y.	Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation.	Am J Gastroenterol .	116(8)	1698-1708	2021
Kokudo N, Kokudo T, <u>Hasegawa K</u> .	Role of Liver Resection for Hepatocellular Carcinoma with Vascular Invasion: Emerging Evidence from Western Countries.	Liver Cancer.	10(5)	404-406	2021
Kudo M, Kawamura Y, <u>Hasegawa K</u> , Tateishi R, Kariyama	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and	Liver Cancer.	10(3)	181-223.	2021

K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T.	Recommendations 2021 Update.				
市田晃彦、有田淳一、石沢武彰、赤松延久、金子順一、 <u>長谷川潔</u>	【肝臓診療2021 アテゾリズマブ+ベバシズマブ登場後の展開】肝細胞癌に対するコンバージョン手術とアテゾリズマブ・ベバシズマブ併用療法	肝臓クリニカルアップデート	7巻1号	29-35	2021
工藤正俊、土谷薫、 <u>長谷川潔</u>	【ここまできた肝細胞癌の薬物療法:2021 update】最新の肝臓薬物療法を語る	肝胆膵	83巻2号	163-179	2021
吉住朋晴、市田晃彦、 <u>長谷川 潔</u>	肝細胞癌の治療における肝移植の位置づけは今後どのように変わっていくか? 適応基準拡大により、肝細胞癌(HCC)合併例の肝移植数増加が予想される(Q&A)	日本医事新報	5071号	46	2021
Kawaratani H, Koike K, <u>Yoshiji H</u> et al.	Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study	J Clin Med.	11(6)	1571	2022
<u>Yoshiji H</u> , Koike K et al.	Evidence-based clinical practice guidelines for liver cirrhosis 2020	Hepato Res	51(7)	725-749	2021
<u>Yoshiji H</u> , Koike K et al.	Evidence-based clinical practice guidelines for liver cirrhosis 2020	J Gastroenterol	56(7)	593-619	2021